Canadian Pharma, Biotech and Life Sciences Stocks

Canopy Growth CEO Bruce Linton explains why he wanted Acreage Holdings

Canadian licensed cannabis producer Canopy Growth (Canopy Growth Stock Quote, Chart TSX:WEED, NYSE:CGC) turned heads last month when it agreed to buy US multi-state operator Acreage Holdings if and when marijuana gets the go-ahead at the federal level, a legislative and social change which still co ...

Buy Theratechnologies for its HIV franchise, Echelon Wealth says

Earlier this year, Endocrinology drug developer Theratechnologies (Theratechnologies Stock Quote, Chart TSX:TH) got a thumbs-up from Echelon Wealth Partners analyst Douglas Loe for its acquisition of Katana Biopharma. Now, in a Thursday update to clients, the analyst reports that preclinical data f ...

Legal weed is already a boring business, this investor says

A couple of new studies on the cannabis industry in Canada have folks wondering how big the market will become and whether all those sky-high sales projections from companies like Canopy Growth, Tilray and Cronos Group will ever be realized. Some have their doubts, including Richard Croft of Croft ...

Take pass on Knight Therapeutics for now, Mackie Research says

It’s still early innings for Knight Therapeutics (Knight Therapeutics Stock Quote, Chart TSX:GUD), says analyst André Uddin of Mackie Research Capital Corporation, who has full faith that battle-tested CEO Jonathan Ross Goodman will eventually make a success out of the Canadian specialty pharma ...

Correvio Pharma has major catalysts on the horizon, Mackie says

Mackie Research analyst André Uddin is sticking to his guns when it comes to specialty pharmaceutical company Correvio Pharma (Correvio Pharma Stock Quote, Chart TSX:CORV), which he says has major catalysts still to come in 2019. Vancouver’s Correvio (formerly Cardiome Pharma) reported its first ...

Canopy Growth Corp’s BC greenhouses are running smoothly, GMP says

Following a tour of Canopy Growth Corp’s (Canopy Growth Corp Stock Quote, Chart TSX:WEED, NYSE:CGC) Aldergrove and Delta facilities, GMP Securities analyst Martin Landry says things are on track. On Tuesday, WEED hosted a tour of its BC facilities, which Landry attended. “The BC greenhouses app ...

Canopy Growth Corp is the 800 pound gorilla of the pot sector, this fund manager says

We’re now over a half-year out from the start of legal recreational marijuana in Canada and while the industry is still taking its first steps, there are still a lot of unknowns about the space. That’s the takeaway for Jason Del Vicario of HollisWealth who says that if he had to pick a winner a ...

Tetra Bio-Pharma has a huge upside, says Paradigm Capital

A new deal by Canopy Growth is clear evidence that cannabis research and drug development company Tetra Bio-Pharma (Tetra Bio-Pharma Stock Quote, Chart TSXV:TBP) is undervalued, says analyst Rahul Sarugaser of Paradigm Capital, who in a research update to clients on Thursday maintained his “Buy ...

Canopy Growth Corp. paid a lot for cannabinoid player C³, GMP says

The acquisition of German cannabinoid compound firm C³ will help Canopy Growth Corp’s (Canopy Growth Corp Stock Quote, Chart TSX, NYSE: WEED) pharmaceutical aspirations, but the Canadian company may have paid a high price for it, GMP Securities analyst Martin Landry says. This morning, Canopy an ...

CRH Medical’s new leadership should take it to the next level, Beacon says

After the fifth consecutive quarter that exceeded expectations, Beacon Securities analyst Doug Cooper says the real story on CRH Medical Corp (CRH Medical Corp. Stock Quote, Chart TSX:CRH NYSE:CRHM)) could be the company’s new CEO. On Wednesday, CRH reported its Q1, 2019 results. The company post ...